Indeed, small molecule LRRK2 inhibitors and antisense oligonucleotides that reduce the expression of LRRK2 are in clinical trials as potential drugs for PD, some of which have completed phase 1/1b and are moving into later stages [145,163]. Here, LRRK2 is linked to Parkinson disease.